Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy
Fudan University
Fudan University
Fujian Cancer Hospital
RemeGen Co., Ltd.
China Medical University, China
Ludwig-Maximilians - University of Munich
Shanghai JMT-Bio Inc.
Hospital Israelita Albert Einstein
Changhai Hospital
Criterium, Inc.
Nanfang Hospital, Southern Medical University
Hôpital Franco-Britannique-Fondation Cognacq-Jay
Second Affiliated Hospital, School of Medicine, Zhejiang University
Salah Azaïz Cancer Institute
Fujian Cancer Hospital
National Cancer Center, Korea
Zhejiang Cancer Hospital
Fujian Medical University
Zhejiang Cancer Hospital
Zhejiang Cancer Hospital
Australasian Gastro-Intestinal Trials Group
Tianjin Medical University Cancer Institute and Hospital
The First Affiliated Hospital of Zhengzhou University
Khon Kaen University
Jiangsu Cancer Institute & Hospital
West China Hospital
Sixth Affiliated Hospital, Sun Yat-sen University
Grupo Espanol Multidisciplinario del Cancer Digestivo
Nanfang Hospital, Southern Medical University
Hallym University Medical Center
China Medical University, China
China Medical University, China
China Medical University, China
Blokhin's Russian Cancer Research Center
Blokhin's Russian Cancer Research Center
Fudan University
Fudan University
Taizhou Hanzhong biomedical co. LTD
Benaroya Research Institute
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sixth Affiliated Hospital, Sun Yat-sen University
Fudan University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Fudan University
Fudan University
Fudan University
ChineseAMS
ChineseAMS
Gruppo Oncologico del Nord-Ovest
Sun Yat-sen University
First Affiliated Hospital of Zhejiang University